Neu auf wallstreet:online?
Jetzt registrieren | Login
x
Benutzername:

Passwort:

Angemeldet bleiben
Passwort vergessen?

Genzyme (GENZ)-Info-Thread (Seite 22)

eröffnet am 10.12.00 18:34:28 von
debull

neuester Beitrag 02.10.08 15:11:44 von
Kara-ben-nemsi
Beiträge: 214
ID: 314.352
Aufrufe heute: 0
Gesamt: 16.584

19.04.11
52,861
0,00 €
0,00 %

Neuigkeiten zur Genzyme Corporation Aktie


Beitrag schreiben Ansicht: Normal
Avatar
seaplane
schrieb am 04.04.08 22:01:26
Beitrag Nr. 211 (33.814.732)
Cowen analysts see rotation in health-care stocks

By Val Brickates Kennedy, MarketWatch
Last update: 3:59 p.m. EDT March 28, 2008

BOSTON (MarketWatch) -- Bracing for a rocky 2008, investors in health-care stocks are increasingly moving their cash out of "one-hit" wonder drug developers and into companies with broader-based product portfolios, according to analysts at Cowen and Co.

In recent interviews, Cowen health-care analysts told MarketWatch that investors are definitely shifting into defensive mode. But as opposed to previous market slowdowns, they're not just fleeing to Big Pharma, the traditional investor's safe haven, but to Big Biotech and medical technology stocks as well.

Big Biotech now defensive plays

"What we've seen is that in the small- and mid-size space, those stocks have traded down pretty considerably. There's much less investor interest today than there was about six months ago," said Phil Nadeau, a biotechnology analyst for Cowen.

Nadeau attributed much of the disaffection to the financial fragility of smaller biotech companies, pointing out that a typical small-cap biotech only has enough cash to operate for 18 to 24 months.

"In a really bad downturn, people worry that those companies wouldn't be able to access the public markets if they need to," Nadeau added.

Instead, Nadeau sees investors taking a strong interest in so-called Big Biotech, particularly top-tier players such as Genentech Inc., Genzyme Corp., Gilead Sciences and Amgen Inc.

"The large-cap space is a bit different because they're almost on the Big Pharma model," Nadeau said. "Those stocks have all held in better than the broader market and that's because they have economically insensitive business models and they have real revenue and earnings."

Big Biotech companies are viewed as "economically insensitive," said Nadeau, because their businesses are "going to grow no matter whether people are losing their jobs or not, or whether there's a credit crunch or not."

Nadeau also sees Big Pharma continuing to seek out smaller biotech companies in order to pump up their deflating product portfolios.
He added that the most attractive takeover targets will be companies that have recently launched a product or are in the final stages of product approval, and can contribute to the top-line within 24 months.

He added that despite the bearish climate, Cowen was advising clients not to give up on biotech entirely.

"We did an analysis of previous bear markets and found that on the way down it's painful to be in biotech," Nadeau said. "But on the way back up, biotech's a great place to be.....it recovers faster and typically goes higher."

"If you're out of biotech during the bad times, you're going to miss that run up to the good times. So we would say, don't avoid biotech, but just to find a place to hide. And the best place to hide seems to be the large caps," Nadeau added.

Hard times for Specialty Pharma

Meanwhile, stocks of specialty pharmaceutical makers are increasingly under pressure.

"You're finding people are much less willing to take bets on binary events and at the same time less willing to take bets on early-stage programs," said Ian Sanderson, who tracks specialty pharmaceutical companies for Cowen.

Sanderson said he also sees Specialty Pharma investors moving toward companies with broader, less-risky portfolios. Generic competition is also an issue. Because many specialty pharmaceuticals are actually reformulations of existing drugs, many investors worry the products are more vulnerable to patent challenges.

"The sector tends to be one- or two-product companies," said Sanderson. "The incidence of patent challenges is so frequent now people are thinking 'Well if they have a good product, someone is going to file a patent challenge on it.'"

Med-tech is back

Meanwhile, things are looking up in the often-overlooked medical technology and supplies sector.

"Anytime you have a slowdown, there's always the thinking that there's going to be a rotation into health care, that it's a bit more defensive," said Cowen's medical technology analyst Doug Schenkel.

"But what obviously complicates things this time around is that you're heading into an election year and there's a lot of questions about what changes could develop from a regulatory standpoint and from a universal health-care standpoint," Schenkel added.

Schenkel attributes med-tech's comeback to its comparatively low-risk profile in comparison to drug developers. A major selling point for the sector is that the regulatory approval process for medical devices tends to be significantly shorter and cheaper than for biotech therapies or pharmaceuticals. And products such as hospital supplies or research tools have almost no regulatory oversight.

"There's just a view that med-tech is a safer place largely because of the R&D challenges that exist in pharma that don't exist in med-tech," said Schenkel.

Schenkel names Medtronic Inc., Johnson & Johnson, Abbott Laboratories, St. Jude Medical, Zimmer Holdings and U.K.-based Smith & Nephew as the leading medical device plays.

"These companies are also a lot smaller, relatively speaking, than companies like Pfizer and Merck, so as a result, there isn't that same concern as to how much you're going to have to spend on R&D to maintain growth," Schenkel added.

Schenkel also sees "renewed and even new" interest in the large molecular diagnostics companies such as Gen-probe Inc., Qiagen N.V and Cepheid. Research toolmakers, such as Applied Biosystems, Affymetrix Inc. and Illumina Inc. are also back into vogue after spending several years on the sidelines.

Traditional diagnostics developers such as Abbott, Beckman Coulter and Becton Dickinson are also getting a second look, said Schenkel, in part because they're also beginning to move into the molecular diagnostics space.
Avatar
debull
schrieb am 18.04.08 09:10:26
Beitrag Nr. 212 (33.915.053)
17.04.2008 07:09
Studie belegt gute Wirksamkeit von MS-Arzneikandidat von Bayer
DÜSSELDORF (Dow Jones)--Der Medikamentenkandidat "Alemtuzumab" gegen Multiple Sklerose (MS) von Bayer ist offenbar noch etwas wirksamer als vorläufige Daten gezeigt hatten. Endgültigen Ergebnissen einer klinischen Phase-II-Studie zufolge, die am Mittwochabend in Chicago präsentiert wurden, verringerte sich das Risiko in der "Alemtuzumab"-Gruppe, einen erneuten Ausbruch der Krankheit zu erleiden, gegenüber der Vergleichsgruppe um mindestens 74%. Die andere Gruppe hatte das Mittel "Rebif" von Merck Serono erhalten. Bisher war die Reduzierung mit "mindestens 73%" angegeben worden.

Das Risiko, dass sich eine Behinderung verschlimmerte, war gegen über der Vergleichstherapie um mindestens 71% vermindert. In den Eckdaten war im vergangenen Herbst noch von 70% die Rede gewesen. In der Präsentation bekräftige der Studienleiter, die seltene Nebenwirkung ITP, bei der es eine abnorme Blutungsneigung gibt, sei durch Bluttests zu kontrollieren und beherrschbar. Seit September 2006 habe es keine neuen Fälle von ITP gegeben. Derzeit laufen zwei klinische Phase-III-Studien mit "Alemtuzumab" gegen MS, in denen mit einem besonderen Programm auf Anzeichen von ITP geachtet wird.

Der monoklonale Antikörper "Alemtuzumab" ist bereits seit 2001 gegen Leukämie zugelassen. Die Bayer AG, Leverkusen, entwickelt ihn gemeinsam mit dem US-Unternehmen Genzyme auch gegen MS; beide Unternehmen wollen die Zulassung in dieser Indikation im Jahr 2011 beantragen. Im Jahr 2012 soll es dann auf den Markt kommen. Das Umsatzpotenzial beziffert Bayer auf 750 Mio bis über 1 Mrd EUR.

Webseite: http://www.bayer.de

DJG/rib/brb
(END) Dow Jones Newswires

April 17, 2008 01:09 ET (05:09 GMT)

© 2008 Dow Jones & Company, Inc.

Avatar
debull
schrieb am 23.04.08 18:18:43
Beitrag Nr. 213 (33.954.619)
23.04.08 15:37
Autor: Aktiencheck (© wallstreet:online AG / Aktiencheck)
zur Originalnachricht
zu allen Artikeln des Autors

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Cambridge, MA (aktiencheck.de AG) - Das amerikanische Biotech-Unternehmen Genzyme Corp. (ISIN US3729171047/ WKN 871137) gab am Mittwoch bekannt, dass es im ersten Quartal einen Gewinnrückgang verzeichnet hat, was vor allem mit einer Sonderbelastung zusammenhängt. Zudem wurde der Ausblick auf 2008 revidiert.

Der Nettogewinn belief sich auf 145,3 Mio. Dollar bzw. 52 Cents pro Aktie, nach 158,2 Mio. Dollar bzw. 57 Cents pro Aktie im Vorjahr. Vor Einmaleffekten lag der Gewinn bei 95 Cents (Vorjahr: 78 Cents) pro Aktie. Der Umsatz nahm um 24,6 Prozent auf 1,10 Mrd. Dollar zu.


Analysten waren zuvor von einem Gewinn von 93 Cents pro Aktie und einem Umsatz von 1,09 Mrd. Dollar ausgegangen. Für das laufende Quartal stellen sie ein EPS-Ergebnis von 96 Cents bei Erlösen von 1,12 Mrd. Dollar in Aussicht.


Für das laufende Geschäftsjahr 2008 rechnet der Konzern nun mit einem bereinigten EPS-Ergebnis von nur noch 3,90 Dollar (zuvor: 4,00 Dollar), was auf die Verzögerung bei der FDA-Zulassung des Medikaments Myozyme zurückzuführen ist. Analysten sehen für 2008 einen Gewinn pro Aktie von 3,95 Dollar.


Die Aktie von Genzyme verliert an der NASDAQ aktuell 0,77 Prozent auf 71,00 Dollar. (23.04.2008/ac/n/a)


Avatar
Kara-ben-nemsi
schrieb am 02.10.08 15:11:44
Beitrag Nr. 214 (35.379.978)
Antwort auf Beitrag Nr.: 33.954.619 von debull am 23.04.08 18:18:43in der letzten zeile bei meinem vorschreiber heisst es: "auf 71 dollar"

Soo, 6 monate später. bear stearn, fannie mae, fredimac, AIG, lehman, usw usw...... sind pleite.....

UND GENZYME STEHT BEI 80 Dollar

soviel dazu, was irgendwelche quartalszahlen bei biotechs wert sind. was juckt mich ein cent weniger gewinn, als in irgendeinem vorzeitraum, wenn die produktpipeline stimmt.
über myozyme wird jetzt im november entschieden. der herbst ist klassischerweise ein starker monat für die biotechs.
und der chart von genzyme sieht doch klasse aus.

unter anderem dank genzyme ist mir diese "Finanzkrise" äusserst gut bekommen.




Beitrag zu dieser Diskussion schreiben

Investoren, die diesen Wert beobachten, informieren sich auch über:

WertpapierPerf. in %
-1,87
0,00
+7,73
0,00
0,00
-14,59
+1,78
0,00
0,00
-0,56